Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting

Immune checkpoint inhibitors (ICIs) are the new frontier for the treatment of advanced hepatocellular carcinoma (HCC). Since the first trial with tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 inhibitor, increasing evidence has confirmed that these drugs can significantly extend the sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Plaz Torres, Maria Corina, Lai, Quirino, Piscaglia, Fabio, Caturelli, Eugenio, Cabibbo, Giuseppe, Biasini, Elisabetta, Pelizzaro, Filippo, Marra, Fabio, Trevisani, Franco, Giannini, Edoardo G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347923/
https://www.ncbi.nlm.nih.gov/pubmed/34361985
http://dx.doi.org/10.3390/jcm10153201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347923/
https://www.ncbi.nlm.nih.gov/pubmed/34361985
http://dx.doi.org/10.3390/jcm10153201

Ejemplares similares